Cefadroxil

Product NDC
57237-097
11-digit product format
572370097
Labeler code
57237
Product ID
57237-097_59b4c983-458c-4363-b2e6-4253a2bc7992
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
Cefadroxil
Dosage form
POWDER, FOR SUSPENSION
Route
ORAL
Labeler
Rising Pharma Holdings, Inc.
Application
ANDA065349
Marketing category
ANDA
Marketing start
2013-04-25
Substance
CEFADROXIL
Active strength
250 mg/5mL
Pharmacologic classes
Cephalosporin Antibacterial [EPC], Cephalosporins [CS]
NDC exclude flag
No
Listing certified through
2026-12-31
Current FDA listing
Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A065349-001CEFADROXILCEFADROXIL/CEFADROXIL HEMIHYDRATEEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25
A065349-002CEFADROXILCEFADROXIL/CEFADROXIL HEMIHYDRATEEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-productTE code
A065349-001AB
A065349-002AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 82 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-02-19 14:30 UTC2026-02A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25011fe1cb6892…
2026-02-19 14:30 UTC2026-02A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-2531067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-2531067a03dcf5…
2025-08-23 18:47 UTC2025-08A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-256a471c1ec25d…
2025-08-23 18:47 UTC2025-08A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-256a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-2503ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-2503ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-252680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-252680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-255bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-255bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25d06236e962d9…
2024-10-29 15:01 UTC2024-10A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-2579d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-2579d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-251e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-251e350fbaab3a…
2024-05-31 18:47 UTC2024-05A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-258072bd15b7f6…
2024-05-31 18:47 UTC2024-05A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-258072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-255c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-255c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-255d02ea3f76ae…
2022-04-08 23:34 UTC2022-04A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-255d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-254b0b4de00fa7…
2022-04-04 05:41 UTC2022-04A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-254b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-2574a2ff9319b5…
2019-12-13 00:20 UTC2019-12A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-2574a2ff9319b5…
2022-03-09 01:35 UTC2022-03A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25bb7c543d1eb4…
2022-03-09 01:35 UTC2022-03A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A065349-001CEFADROXILEQ 250MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25782e0a99824c…
2021-12-28 21:50 UTC2021-12A065349-002CEFADROXILEQ 500MG BASE/5MLFOR SUSPENSION / ORALAB2013-04-25782e0a99824c…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 3 · 82 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-02-19 14:30 UTC2026-02A065349-001AB1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A065349-002AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A065349-001AB131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A065349-002AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A065349-001AB16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A065349-002AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A065349-001AB1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A065349-002AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A065349-001AB1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A065349-002AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A065349-001AB103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A065349-002AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A065349-001AB12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A065349-002AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A065349-001AB15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A065349-002AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A065349-001AB1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A065349-002AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A065349-001AB1d06236e962d9…
2024-10-29 15:01 UTC2024-10A065349-002AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A065349-001AB179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A065349-002AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A065349-001AB1301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A065349-002AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A065349-001AB11e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A065349-002AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A065349-001AB18072bd15b7f6…
2024-05-31 18:47 UTC2024-05A065349-002AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A065349-001AB15c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A065349-002AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A065349-001AB15d02ea3f76ae…
2022-04-08 23:34 UTC2022-04A065349-002AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A065349-001AB14b0b4de00fa7…
2022-04-04 05:41 UTC2022-04A065349-002AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A065349-001AB174a2ff9319b5…
2019-12-13 00:20 UTC2019-12A065349-002AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A065349-001AB1bb7c543d1eb4…
2022-03-09 01:35 UTC2022-03A065349-002AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A065349-001AB1782e0a99824c…
2021-12-28 21:50 UTC2021-12A065349-002AB1782e0a99824c…

Additional Listing Data#

Finished product
Yes
Brand name base
Cefadroxil
Listing expiration
2026-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
CEFADROXIL250 mg/5mL

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
280111G160Internal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 2 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
105171Internal RxNorm lookup
309048Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
6e4111d3-f11b-403c-b340-b216022709dfAvailable on FDA.report

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
560bed03-0257-a1db-0638-2c46fc35054cProduct name220170824
34f1b9ee-0673-df8c-ddae-36eaf4c48382Product name120140508
3793572a-4958-68b2-f923-8cf695ec1cc1Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
57237-097-01Cefadroxil100 mL in 1 BOTTLEPOWDER, FOR SUSPENSION1006
57237-097-50Cefadroxil50 mL in 1 BOTTLEPOWDER, FOR SUSPENSION506

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
57237-097-01ML - Milliliter57237-097431c9fd9-09bd-4a7d-8167-78fc1aee1cb212015-02-02

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
CEFADROXILACTIVE INGREDIENT280111G160CEFADROXIL POWDER, FOR SUSPENSION [CITRON PHARMA LLC]1
CEFADROXIL ANHYDROUSACTIVE MOIETYQ525PA8JJBCEFADROXIL POWDER, FOR SUSPENSION [CITRON PHARMA LLC]1
FD&C YELLOW NO. 6INACTIVE INGREDIENTH77VEI93A8CEFADROXIL POWDER, FOR SUSPENSION [CITRON PHARMA LLC]1
POLYSORBATE 80INACTIVE INGREDIENT6OZP39ZG8HCEFADROXIL POWDER, FOR SUSPENSION [CITRON PHARMA LLC]1
SODIUM BENZOATEINACTIVE INGREDIENTOJ245FE5EUCEFADROXIL POWDER, FOR SUSPENSION [CITRON PHARMA LLC]1
SUCROSEINACTIVE INGREDIENTC151H8M554CEFADROXIL POWDER, FOR SUSPENSION [CITRON PHARMA LLC]1
SULFUR DIOXIDEINACTIVE INGREDIENT0UZA3422Q4CEFADROXIL POWDER, FOR SUSPENSION [CITRON PHARMA LLC]1
XANTHAN GUMINACTIVE INGREDIENTTTV12P4NEECEFADROXIL POWDER, FOR SUSPENSION [CITRON PHARMA LLC]1

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
57237-097CEFADROXIL POWDER, FOR SUSPENSION [RISING PHARMA HOLDINGS, INC.]6Current NDC, Legacy NDC, 2 package rows20240215_6e4111d3-f11b-403c-b340-b216022709df.zip

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 3 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CefadroxilCEFADROXILNorthStar Rx LLC30bb3686-87b4-4676-9ff5-e20deb8bff9d2024-02-09Warnings, Adverse reactionsExact identifier
application applno (ANDA): 065349
application number: ANDA065349
CefadroxilCEFADROXILRising Pharma Holdings, Inc.6e4111d3-f11b-403c-b340-b216022709df2024-02-09Warnings, Adverse reactionsExact identifier
application applno (ANDA): 065349
application number: ANDA065349
ndc (product): 57237-097
CefadroxilCEFADROXILAurobindo Pharma Limited776a8dbc-e68e-4732-acf4-0133dca0f54c2024-02-09Warnings, Adverse reactionsExact identifier
application applno (ANDA): 065349
application number: ANDA065349

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
309048cefadroxil 250 MG in 5 mL Oral SuspensionPSN6e4111d3-f11b-403c-b340-b216022709df6
105171cefadroxil 500 MG in 5 mL Oral SuspensionPSN6e4111d3-f11b-403c-b340-b216022709df6
105171cefadroxil 100 MG/ML Oral SuspensionSCD6e4111d3-f11b-403c-b340-b216022709df6
309048cefadroxil 50 MG/ML Oral SuspensionSCD6e4111d3-f11b-403c-b340-b216022709df6
105171cefadroxil (as cefadroxil monohydrate) 100 MG/ML Oral SuspensionSY6e4111d3-f11b-403c-b340-b216022709df6
309048cefadroxil (as cefadroxil monohydrate) 50 MG/ML Oral SuspensionSY6e4111d3-f11b-403c-b340-b216022709df6
309048cefadroxil 250 MG per 5 ML Powder for Oral SuspensionSY6e4111d3-f11b-403c-b340-b216022709df6
105171cefadroxil 500 MG per 5 ML Powder for Oral SuspensionSY6e4111d3-f11b-403c-b340-b216022709df6

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startMarketing endSampleExclude flagStatus
57237-097-0157237009701100 mL in 1 BOTTLE (57237-097-01) 100 ml2013-04-250000-00-00NoNoCurrent
57237-097-505723700975050 mL in 1 BOTTLE (57237-097-50) 50 ml2013-04-250000-00-00NoNoCurrent